Abstracts tagged "medication"

Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Philip J. Mease¹, Emily Edson-Heredia², Katherine C. Saunders³, Catherine L. Shuler², Baojin Zhu², Monica Chaudhari⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Eli Lilly and Company, Indianapolis, IN, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…
Abstract Number: 270 • 2012 ACR/ARHP Annual Meeting
Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Daniel Prieto-Alhambra¹ and Rosa Morros², ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Spain
TITLE: "Use of drug combinations in patients with osteoarthritis: a population-based cohort study."Background/Purpose: Patients affected with osteoarthritis (OA) use different drugs in search for relief.…
Abstract Number: 2484 • 2012 ACR/ARHP Annual Meeting
Hepatic Steatosis in Rheumatoid Arthritis: Associations with Disease Characteristics, Pharmacotherapies, and Atherosclerosis
Jon T. Giles¹ and Joan M. Bathon², ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Columbia University, New York, NY
Background/Purpose: Ectopic deposition of liver fat (steatosis) is associated with insulin resistance (IR), cardiovascular disease (CVD), and is a potent risk factor for cirrhosis. RA…
Abstract Number: 2462 • 2012 ACR/ARHP Annual Meeting
Projecting the Direct Cost Burden of Osteoarthritis in Canada Using a Population-Based Microsimulation Model From [2010-2031]
Behnam Sharif¹, Jacek A. Kopec², Mushfiqur Rahman³, Nick Bansback⁴, Eric C. Sayre², Philippe Finès⁵, Hubert Wong⁶ and Aslam H. Anis⁴, ¹School of Population and Public Health, University of British Columbia, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵Statistics Canada, 150 Tunney's Pasture Driveway, Ottawa, ON, Canada, Ottawa, ON, Canada, ⁶School of Population and Public Health, University of British Columbia, St Paul's Hospital, University of British Columbia, Vancouver, V6Z 1Y6, Canada, Vancouver, BC, Canada
Background/Purpose: POHEM-OA (Population Health Model-Osteoarthritis) is a population-based microsimulation model that uses Canadian Community Health Survey-2001 to generate the initial population and models every individual's…
Abstract Number: 2028 • 2012 ACR/ARHP Annual Meeting
Medication Adherence and Quality of Life in Children with Rheumatic Disease
Stacey E. Tarvin¹, Lisa M. Macharoni², Christine M. Raches³ and Nicole M. Taylor², ¹Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ²School of Psychological Sciences, University of Indianapolis, Indianapolis, IN, ³Riley Child Development Center, Riley Hospital for Children, Indianapolis, IN
Background/Purpose: Children with rheumatic diseases are often prescribed complex medication regimens. Medication side-effects may have a negative impact on physical appearance and subsequently impact adherence. …
Abstract Number: 906 • 2012 ACR/ARHP Annual Meeting
Patient-Rheumatologist Communication Concerning Medication and Disease Risks
Susan J. Blalock, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Medications play an important role in the management of rheumatoid arthritis. Principles of informed consent, informed and shared decision-making, and professional ethics highlight the importance…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].